Screening and human health risk assessment of pharmaceuticals and their transformation products in Dutch surface waters and drinking water

Science of the Total Environment

Volumn 427-428, Issue , 2012, Pages 70-77

  de Jongh, Cindy M ^a   Kooij, Pascal J F ^a   de Voogt, Pim ^a   ter Laak, Thomas L ^a  

^a KWR WATERCYCLE RESEARCH INSTITUTE   (Netherlands)

Author keywords

Drinking water; Human health risk assessment; Pharmaceuticals; Transformation products; Water cycle

Indexed keywords

ADDITIVITY; ADVERSE HEALTH EFFECTS; CONCENTRATION LEVELS; CONSTANT RATIO; DUTCH SURFACE WATERS; GUIDELINE VALUES; HUMAN HEALTH RISK ASSESSMENT; LOW CONCENTRATIONS; NETHERLANDS; PHARMACOLOGICAL ACTIVITY; RELATED COMPOUNDS; RIVER BANK; STATISTICAL UNCERTAINTY; SYNERGISTIC EFFECT; TRANSFORMATION PRODUCTS; WATER CYCLE; WATER TYPES;

BANKS (BODIES OF WATER); DRUG PRODUCTS; GROUNDWATER; POTABLE WATER; RISK ASSESSMENT;

SURFACE WATERS;

1 ACETYL 1 METHYL 2 PHENYLHYDRAZIDE; 4 ACETYLAMINOANTIPYRINE; 4 FORMYLAMINOANTIPYRINE; AMINOPHENAZONE; ATENOLOL; BEZAFIBRATE; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CLINDAMYCIN; DESVENLAFAXINE; DRINKING WATER; DRUG; ERYTHROMYCIN; GROUND WATER; METOPROLOL; O NORTRAMADOL; OXCARBAZEPINE; PHENAZONE; PROPYPHENAZONE; RIVER BANK FILTRATE; RIVER WATER; SOTALOL; SURFACE WATER; TRAMADOL; TRANSFORMATION PRODUCT; UNCLASSIFIED DRUG; VENLAFAXINE;

CONCENTRATION (COMPOSITION); DRINKING WATER; DRUG; HEALTH RISK; RISK ASSESSMENT; SURFACE WATER; TOXICOLOGY; TRANSFORMATION;

ANALYTICAL PARAMETERS; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HEALTH HAZARD; NETHERLANDS; PREDICTION; PRIORITY JOURNAL; PROVISIONAL GUIDELINE VALUE; RISK ASSESSMENT; SCREENING; WATER CONTAMINATION; WATER CYCLE; WATER SAMPLING;

DRINKING WATER; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; FRESH WATER; HUMANS; NETHERLANDS; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; WATER POLLUTANTS, CHEMICAL;

NETHERLANDS;

EID: 84861186616     PISSN: 00489697     EISSN: 18791026     Source Type: Journal    
DOI: 10.1016/j.scitotenv.2012.04.010     Document Type: Article

References (41)

1. Bennett G.D., Amore B.M., Finnell R.H., Wlodarczyk B., Kalhorn T.F., Skiles G.L., et al. Teratogenicity of carbamazepine-10,11-epoxide and oxcarbazepine in the SWV mouse. J Pharmacol Exp Ther 1996, 279:1237-1242.
2. Boobis A., Budinsky R., Collie S., Crofton K., Embry M., Felter S., et al. Critical analysis of literature on low-dose synergy for use in screening chemical mixtures for risk assessment. Crit Rev Toxicol 2011, 41:369-383.
3. Bruce G.M., Pleus R.C., Snyder S.A. Toxicological relevance of pharmaceuticals in drinking water. Environ Sci Technol 2010, 44:5619-5626.
4. Brune K. The early history of non-opioid analgesics. Acute Pain 1997, 1:33-40.
5. Bull R.J., Crook J., Whittaker M., Cotruvo J.A. Therapeutic dose as the point of departure in assessing potential health hazards from drugs in drinking water and recycled municipal wastewater. Regul Toxicol Pharmacol 2011, 60:1-19.
6. Chitil L., Sticha M., Matouskova O., Perlik F., Slanar O. Enantiomeric determination of tramadol and O-desmethyltramadol in human urine by gas chromatography-mass spectrometry. J Chromatogr B 2009, 877:1937-1942.
7. Cunningham V.L., Binks S.P., Olson M.J. Human health risk assessment from the presence of human pharmaceuticals in the aquatic environment. Regul Toxicol Pharmacol 2009, 53:39-45.
8. Cunningham V.L., Perino C., D'Aco V.J., Hartmann A., Bechter R. Human health risk assessment of carbamazepine in surface waters of North America and Europe. Regul Toxicol Pharmacol 2010, 56:343-351.
9. de Moel P.J., Verberk J.Q.J.C., van Dijk J.C. Drinking water; principles and practices 2006, World Scientific Publishing, Singapore.
10. EMEA Committee for Veterinary Medicinal Products - Metamizole - Summary Report (2), EMEA/MRL/878/03 2003, European Agency for the Evaluation of Medicinal Products (EMEA), London.
11. Escher B.I., Fenner K. Recent advances in environmental risk assessment of transformation products. Environ Sci Technol 2011, 45:3835-3847.
12. Feldmann D.F., Zuehlke S., Heberer T. Occurrence, fate and assessment of polar metamizole (dipyrone) residues in hospital and municipal wastewater. Chemosphere 2008, 71:1754-1764.
13. Gaylor D.W., Swirsky Gold L. Regulatory cancer risk assessment based on a quick estimate of a benchmark dose derived from the maximum tolerated dose. Regul Toxicol Pharmacol 1998, 28:222-225.
14. Haas C.N., Scheff P.A. Estimation of averages in truncated samples. Environ Sci Technol 1990, 24:912-919.
15. Howell S.R., Husbands G.E.M., Scatina J.A., Sisenwine S.F. Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 1993, 23:349-359.
16. Kern S., Fenner K., Singer H.P., Schwarzenbach R.P., Hollender J. Identification of transformation products of organic contaminants in natural waters by computer-aided prediction and high-resolution mass spectrometry. Environ Sci Technol 2009, 43:7039-7046.
17. Kern S., Baumgartner R., Helbling D.E., Hollender J., Singer H., Loos M.J., et al. A tiered procedure for assessing the formation of biotransformation products of pharmaceuticals and biocides during activated sludge treatment. J Environ Monit 2010, 12:2100-2111.
18. Kumar A., Chang B., Xagoraraki I. Human health risk assessment of pharmaceuticals in water: issues and challenges ahead. Int J Environ Res Public Health 2010, 7:3929-3953.
19. Levy M., Zylber-Katz E., Rosenkranz B. Clinical pharmacokinetics of dipyrone and its metabolites. Clin Pharmacokinet 1995, 28:216-234.
20. Medicines Complete Martindale-the complete drug reference 2011, Pharmaceutical press.
21. Mezcua M., Malato O., Garcia-Reyes J.F., Molina-Diaz A., Fernandez-Alba A.R. Accurate-mass databases for comprehensive screening of pesticide residues in food by fast liquid chromatography time-of-flight mass spectrometry. Anal Chem 2009, 81:913-929.
22. Miao X.S., Metcalfe C.D. Determination of carbamazepine and its metabolites in aqueous samples using liquid chromatography-electrospray tandem mass spectrometry. Anal Chem 2003, 75:3731-3738.
23. Monteiro S.C., Boxall A.B.A. Occurrence and fate of human pharmaceuticals in the environment. Rev Environ Contam Toxicol 2010, 53-154.
24. National Library of Medicine DailyMed-current medication information 2010.
25. Reddersen K., Heberer T., Dunnbier U. Identification and significance of phenazone drugs and their metabolites in ground- and drinking water. Chemosphere 2002, 49:539-544.
26. Richardson S.D., Plewa M.J., Wagner E.D., Schoeny R., DeMarini D.M. Occurrence, genotoxicity, and carcinogenicity of regulated and emerging disinfection by-products in drinking water: a review and roadmap for research. Mutat Res Rev Mutat Res 2007, 636:178-242.
27. Rohweder U. Pharmaceuticals in the environment: assessment of results. Arzneimittel in der Umwelt: Auswertung der Untersuchungsergebnisse 2003, 175. Bund/Länderausschuss für Chemikaliensicherheit, Hamburg, Germany.
28. Roig B. Pharmaceuticals in the environment-current knowledge and need assessment to reduce presence and impact 2010, 198. IWA, London, UK.
29. Schriks M., Heringa M.B., van der Kooi M.M., de Voogt P., van Wezel A.P. Toxicological relevance of emerging contaminants for drinking water quality. Water Res 2010, 44:461-476.
30. Schwab B.W., Hayes E.P., Fiori J.M., Mastrocco F.J., Roden N.M., Cragin D., et al. Human pharmaceuticals in US surface waters: a human health risk assessment. Regul Toxicol Pharmacol 2005, 42:296-312.
31. Snyder S.A., Trenholm R.A., Snyder E.M., Bruce G.M.P., Hemming J.D.C. Toxicological relevance of ECDs and pharmaceuticals in drinking water 2008, 484. Awwa Research Foundation, Denver, USA.
32. ter Laak T.L., Van der Aa M., Stoks P., Houtman C., van Wezel A.P. Relating environmental concentrations of pharmaceuticals to consumption: a mass balance approach for the river Rhine. Environ Int 2010, 36:403-409.
33. Testa B., Kramer S.D. The biochemistry of drug metabolism-an introduction: part 4. Reactions of conjugation and their enzymes. Chem Biodivers 2008, 5:2171-2336.
34. U.S.Environmental Protection Agency EPI-suite, KOWWIN version 1.67a 2000, Environmental Protection Agency.
35. van der Aa N.G.F.M., Dijkman E., Bijlsma L., Emke E., van de Ven B.M., van Nuijs A.L.N., et al. Drugs of abuse and tranquilizers in Dutch surface waters, drinking water and wastewater 2011, National Institute of Public Health and the Environment, Bilthoven.
36. Vermeire T.G., Baars B.J., Bessems J.G.M., Blaauboer B.J., Slob W., Muller J.J.A. Toxicity testing for human health risk assessment. Risk assessment of chemicals-an introduction 2007, Springer, Dordrecht. C.J. van Leeuwen, T.G. Vermeire (Eds.).
37. Versteegh J.F.M., Stolker A.A.M., Niesing W., Muller J.J.A. Pharmaceuticals in drinking water and sources of drinking water-results of monitoring campaign 2002 (geneesmiddelen in drinkwater en drinkwaterbronnen - resultaten van het meetprogramma 2002) 2003, RIVM, Bilthoven.
38. Versteegh J.F.M., van der Aa N.G.F.M., Dijkman E. Pharmaceuticals in drinking water and sources of drinking water-results of monitoring campaign 2005/2006 (geneesmiddelen in drinkwater en drinkwaterbronnen - resultaten van het meetprogramma 2005/2006) 2007, RIVM, Bilthoven.
39. WHO Toxicological evaluation of certain veterinary drug residues in food - WHO Food Additives series 45 - lincomycin 2000, Geneva.
40. WHO Pharmaceuticals in drinking-water 2011, WHO/HSE/WSH/11.05, World Health Organization, Geneva.
41. Zuehlke S., Duennbier U., Heberer T. Investigation of the behavior and metabolism of pharmaceutical residues during purification of contaminated ground water used for drinking water supply. Chemosphere 2007, 69:1673-1680.